ATE250940T1 - Zielgerichte ortsspezifische arzneimittelzusammensetzungen und verwendungen - Google Patents

Zielgerichte ortsspezifische arzneimittelzusammensetzungen und verwendungen

Info

Publication number
ATE250940T1
ATE250940T1 AT99933960T AT99933960T ATE250940T1 AT E250940 T1 ATE250940 T1 AT E250940T1 AT 99933960 T AT99933960 T AT 99933960T AT 99933960 T AT99933960 T AT 99933960T AT E250940 T1 ATE250940 T1 AT E250940T1
Authority
AT
Austria
Prior art keywords
microbubbles
therapeutic
site
delivery
specific drug
Prior art date
Application number
AT99933960T
Other languages
English (en)
Inventor
Thomas R Porter
Patrick L Iversen
Gary D Meyer
Original Assignee
Univ Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/114,399 external-priority patent/US6245747B1/en
Priority claimed from US09/118,168 external-priority patent/US6117858A/en
Application filed by Univ Nebraska filed Critical Univ Nebraska
Application granted granted Critical
Publication of ATE250940T1 publication Critical patent/ATE250940T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99933960T 1998-07-13 1999-07-13 Zielgerichte ortsspezifische arzneimittelzusammensetzungen und verwendungen ATE250940T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/114,399 US6245747B1 (en) 1996-03-12 1998-07-13 Targeted site specific antisense oligodeoxynucleotide delivery method
US09/118,168 US6117858A (en) 1996-06-28 1998-07-17 Compositions and methods for altering the biodistribution of biological agents
PCT/US1999/015801 WO2000002588A1 (en) 1998-07-13 1999-07-13 Targeted site specific drug delivery compositions and method of use

Publications (1)

Publication Number Publication Date
ATE250940T1 true ATE250940T1 (de) 2003-10-15

Family

ID=26812136

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99933960T ATE250940T1 (de) 1998-07-13 1999-07-13 Zielgerichte ortsspezifische arzneimittelzusammensetzungen und verwendungen

Country Status (7)

Country Link
EP (1) EP1094843B1 (de)
JP (1) JP2002520298A (de)
AT (1) ATE250940T1 (de)
AU (1) AU743695B2 (de)
CA (1) CA2337361C (de)
DE (1) DE69911777T2 (de)
WO (1) WO2000002588A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60143085D1 (de) * 2000-05-17 2010-10-28 Univ Nebraska Morpholino antisense oligomere als enzyminhibitoren zur verbesserung der pharmacokinetik eines wirkstoffs
JP2002145784A (ja) * 2000-11-10 2002-05-22 Ryuichi Morishita 生物学的活性薬剤導入組成物およびその使用方法
DE10108798A1 (de) * 2001-02-19 2002-09-26 Laser & Med Tech Gmbh Verfahren und Vorrichtung zur ultraschallgestützten transmembranen Medikamentenapplikation in vivo
AU2002241270A1 (en) * 2002-03-22 2003-10-08 Anges Mg, Inc. Compositions for delivering biologically active drug and method of using the same
US7754238B2 (en) 2002-05-03 2010-07-13 Avi Biopharma, Inc. Delivery of microparticle-conjugated drugs for inhibition of stenosis
US20030207907A1 (en) 2002-05-03 2003-11-06 Iversen Patrick L. Delivery of microparticle-conjugated drugs for inhibition of stenosis
DE10223196B4 (de) 2002-05-24 2004-05-13 Dornier Medtech Systems Gmbh Verfahren und Einrichtung zum Transferieren von Molekülen in Zellen
ES2351976T3 (es) 2003-04-29 2011-02-14 Avi Biopharma, Inc. Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células.
DE602005019367D1 (de) 2004-12-15 2010-04-01 Dornier Medtech Systems Gmbh Verbesserte Zelltherapie und Gewebsregeneration mittels Stosswellen bei Patienten mit kardiovaskulären and neurologischen Krankheiten
WO2007028981A1 (en) * 2005-09-08 2007-03-15 University Of Dundee Apparatus and method for sonoporation
ES2657400T3 (es) 2006-05-10 2018-03-05 Sarepta Therapeutics, Inc. Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos
AU2008271050B2 (en) 2007-06-29 2014-11-06 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
US9044542B2 (en) 2007-12-21 2015-06-02 Carticept Medical, Inc. Imaging-guided anesthesia injection systems and methods
US8002736B2 (en) 2007-12-21 2011-08-23 Carticept Medical, Inc. Injection systems for delivery of fluids to joints
US8545440B2 (en) 2007-12-21 2013-10-01 Carticept Medical, Inc. Injection system for delivering multiple fluids within the anatomy
WO2014117232A1 (pt) * 2013-02-04 2014-08-07 Farret Neto Abdo Preparação medicinal sob a forma de espuma para a liberação prolongada de medicamentos e sistema para obtenção da preparação medicinal

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5567415A (en) * 1993-05-12 1996-10-22 The Board Of Regents Of The University Of Nebraska Ultrasound contrast agents and methods for their manufacture and use
GB9502065D0 (en) * 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
US5997898A (en) * 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
ATE248511T1 (de) * 1996-03-12 2003-09-15 Univ Nebraska Zusammensetzung zur zielortspezifischen verabreichung eines medikamentes und verfahren zur anwendung
US5849727A (en) * 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
WO1998018498A2 (en) * 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents

Also Published As

Publication number Publication date
EP1094843A1 (de) 2001-05-02
AU4989999A (en) 2000-02-01
WO2000002588A1 (en) 2000-01-20
AU743695B2 (en) 2002-01-31
JP2002520298A (ja) 2002-07-09
CA2337361C (en) 2010-11-16
DE69911777T2 (de) 2004-04-29
DE69911777D1 (de) 2003-11-06
EP1094843B1 (de) 2003-10-01
CA2337361A1 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
ATE250940T1 (de) Zielgerichte ortsspezifische arzneimittelzusammensetzungen und verwendungen
ATE264114T1 (de) Zyklodexrinpolymere zum gebrauch als medikamententräger
Han et al. Combination of Metal‐Phenolic Network‐Based Immunoactive Nanoparticles and Bipolar Irreversible Electroporation for Effective Cancer Immunotherapy
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
BR9917089A (pt) Composições e métodos para distribuição mucosal
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
DE60220408D1 (de) Sequenzielles arzneimittelabgabesystem
MXPA05002814A (es) Formulacion para agentes lipofilicos.
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
MY167123A (en) Conveniently implantable sustained release drug compositions
DE69931930D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
MXPA02010801A (es) Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados.
TR200101867T2 (tr) CCR5 modülatörleri olarak piperidinler
BRPI0415971A (pt) método para tratar, prevenir ou controlar degeneração macular, e, composição farmacêutica
MXPA05003591A (es) Materiales basados en ciclodextrina, composiciones y usos relacionados a los mismos.
BRPI0407897A (pt) derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios
SG148169A1 (en) Combination drug therapy to treat obesity
AU2207197A (en) Targeted site specific drug delivery compositions and method of use
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
EP1178988A4 (de) Verbindungen und therapeutische methoden
EP1392328A4 (de) Krebstherapie
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
PT1358177E (pt) Tratamento de desordens afectivas atraves da accao combinada de um agonista do receptor nicotinico e uma substancia manoaminergica
ATE382356T1 (de) Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1094843

Country of ref document: EP